James Brigaitis

Biography

Jim Brigaitis has more than 30 years of experience as a pharmaceutical and biologics marketing executive. During his career, Jim has held senior positions in diverse organizations ranging from the world’s largest pharmaceutical company to a start-up firm.

A key focus during Jim’s career has been launching complex innovations and transforming biopharmaceutical markets. He has led the strategic planning and marketing efforts for a number of multi-billion dollar products that have redefined the standard of care in a variety of disease categories. These include Aricept (alzhiemer’s disease), Diflucan (infectious diseases), Lyrica (pain and fibromyagia), Viagra (erectile dysfunction), and Zoloft (depression).

Jim is currently the President and Founder of a consulting firm that specializes in commercial strategy for new and emerging biopharmaceutical companies. Prior to that, Jim was Vice President of Worldwide Marketing and Commercial Development for Pfizer’s $7 billion neurosciences portfolio. He was also a member of a small executive team that secured venture capital funding to form a new company that successfully developed and out-licensed a novel antibiotic (Solosec).

Education

• MBA The University of Chicago Booth School of Business
• BA Northwestern University

Companies

• Adjunct Professor NYU Stern School of Business (2017)
• President & Founder Brigaitis & Associates (2008)
• Vice President, Asset Strategist Syneos Health (2018 — 2020)
• Founding Member & Commercial Advisor Symbiomix Therapeutics, LLC (2010 — 2016)
• VP | Worldwide Marketing & Commercial Development Pfizer Inc. (1986 — 2007)
• Vice President | Group Leader | US & Worldwide Marketing Pfizer Inc (1986 — 2007)